DeutschesFachbuch.de : Essentials of Restenosis For the Interventional Cardiologist

INHALTSVERZEICHNIS | öffnen

Contents
Prefacev
Contributorsix
List of Color Platesixii
PART I. PATHOPHYSIOLOGY AND DIAGNOSIS
1.Unraveling the Complex Process of Restenosis From Bench to Bedside 3
Henricus J. Dückers, Caroline Cheng, Dennie Tempel, and Patrick W. Serruys
2.Epidemiology and Pathogenesis of Restenosis 7
Randolph L. Geary and Alexander W. Clowes
3.Clinical Presentation of Restenosis 29
Ganesh Manoharan, Giedrius Davidavicius, and William Wijns
4.Pathological Anatomy of Restenosis 47
Renu Virmani, Frank D. Kolodgie, Aloke V. Finn, and Herman K. Gold
5.The Influence of Shear Stress on Restenosis 59
Attila Thury, Jolanda J. Wentzel, Frank J. H. Gijsen, Johan C. H. Schuurb...
6.The Immune System in the Pathogenesis of Vascular Proliferative Disease 85
Jon D. Laman and Burkhard Ludewig
7.Animal Restenosis Models: From the Ideal Model to the Ideal Study 131
Arturo G. Touchard and Robert S. Schwartz
PART II. GENETIC BASIS OF RESTENOSIS
8.The Genomics of Restenosis 153
Thomas W. Johnson and Karl R. Karsch
9.Gene-Expression Profiling and Restenosis 167
Dietlind Zohlnhöfer and Franz-Josef Neumann
10.Proteomics and Restenosis 175
Santhi K. Ganesh and Elizabeth G. Nabel
11.Contribution of Circulating Progenitor Cells to Vascular Repair and Lesio...
Masataka Sata and Kenneth Walsh
12.Cell Cycle Regulators and Vascular Proliferative Diseases 199
Andrew Wragg and Manfred Boehm
13.Arterial Remodeling 213
Gerard Pasterkamp, Bradley H. Strauss, and Dominique de Kleijn
14.The Role of eNOS in Vascular Diseases 227
Alexey Kuroedov, Francesco Cosentino, Felix C. Tanner, and Thomas F. Liisch...
PART III. DIAGNOSIS OF RESTENOSIS
15.The Use of Pressure Gradient in the Diagnosis of Restenosis 247
Volker Klaus and Nico H. J. Pijls
16.The Use of Radio Isotopes in the Diagnosis of Vascular-Proliferative Dis...
Giedrius Davidavicius, Ganesh Manoharan, and William Wijns
17.Magnetic Resonance Imaging for Restenosis 277
Robert Jan M. van Geuns and Timo Baks
18.Coronary Imaging With Multislice Spiral Computed Tomography 287
Koen Nieman
PART IV. THERAPY OF RESTENOSIS
19.Pharmacotherapy of Restenosis 301
Pirn J. de Feyter and Georgios Sianos
20.Brachytherapy 307
Ron Waksman
21.Preclinical Data of Eluting Stents 333
Antonio Colombo and-Alaide Chieffo
22.Clinical Data of Eluting Stents 353
Marco A. Costa, Alexandre Abizaid, Amanda G. M. R. Sousa, and J. Eduardo ...
23.Biodegradable Stents 369
Takafumi Tsuji, Hideo Tamai, and Keiji Igaki
PART V. BIOTECHNOLOGY IN THE TREATMENT OF RESTENOSIS
24.Vascular Gene Therapy 379
Gurpreet S. Sandhu and Robert D. Simari
25.Antisense and ODN Transcription Factors in the Treatment of Vascular Pro...
Nicholas Kipshidze, Mykola Tsapenko, George Dangas, and Pat Iversen
26.Cell Cycle Approaches to the Treatment of In-Stent Restenosis 407
Elizabeth G. Nabel
27.Local Gene and Cell Delivery Devices 419
Ravish Sachar and Eric J. Topol
Index 443
[weiter lesen]

REGISTER | öffnen

Index
AAAV vectors, 383, 385, 390-392
Abciximab (Reopro®)
- BARI data, 9
- EPIC data, 16
as therapy, 304
ABI alloy stents, 280
ABT-578
- DES, 339, 344, 356, 359
Acetylcholine in arterial relaxation, 236
- FActin, response to shear stress, 61
Actinomycin-D DES
animal studies of, 342
- clinical studies of, 342, 356, 362
- overview, 56, 333
ACTION study, 342, 356, 362
Adaptive immunity
- in atherosclerosis, 109-110
- described, 88-89
- receptors, 88
- regulation of, 115, 116
Adenosine diphosphate in arterial
- relaxation, 236
Adenovirus vectors, 208, 379, 383-385, 390
Adhesion molecules. See also specific molecules in atherosclerosis, 200
and SMC hyperplasia, 187, 192
Adipokines described, 106, 107
Advanced glycosylation end products (AGE), 181
Aggressive restenosis, predictors of, 31
AGI 1067, 303
Akt signaling, 229
Aminolaevulinic acid, 220
Aneurysm formation, 21
Angina
- pectoris, 262, 266, 272
- recurrent, 279
- unstable, 32, 35, 36
Angiogenesis promotion, eNOS in, 237-238
Angiography
- CT, 289
- limitations of, 141, 142, 247-248, 263
- MR, 277
- vs MPI, 265, 272
Angiopeptin DES, 356, 362
Angioplasty
- balloon. See Balloon angioplasty
- BARI data, 9
- lumen narrowing, mechanisms of, 15
- remodeling following, 19-20, 213-215, 336
- restenosis pathology following, 136
- restenosis rates, average, 8
Angiotensin II, 17, 215
ANGUS technique
applications of, 68, 70, 71, 73
- described, 63
Animal models. See also specific animals
- of atherosclerosis, 143-144
- drug studies, 139-144
- elastic recoil/remodeling, 139, 140
- gene expression profiling, 170
- of inflammation, 138, 139
- injury response, species-specific, 135-139
- in-stent restenosis, 337
- limitations of, 160-161
- overview, 131-132, 144-145
Antibodies described, 98
Anticoagulants, 16, 17, 138
Antigen presenting cells (APC)
- costimulatory molecule interactions, 103
- described, 98, 101-102
Antioxidants, 302-303
Antiplatelet drugs, 16, 48, 312
Antisense oligonucleotides (ODNs)
- cellular uptake of, 399
- clinical trials of, 400-402
- delivery systems, 399-400, 420
- rationale, for NIH, 397-398
- SMC proliferation, inhibition of, 398-399
Antithrombotic agents, 138
Apoptosis
- p 21 Cipl inhibition of, 410
- in SMCs, 19, 239
- L-Arginine
arterial hypertension and, 232-233
as remodeling intervention, 219, 233, 304
Arrhythmia, MSCT imaging of, 292
Arterial hypertension, NO and, 232-233
Arteries
- hemodynamic forces acting on, 59-60
- injury documentation issues, 142-143
shear stress, adaptations to, 60-61
Arteriosclerosis, transplant-associated, 187-188
ARTISTIC trials, 310, 312, 317
ARTS-2 study, 355, 365
ASPECT study, 38, 40, 208, 355, 361-362
Aspirin
- restenosis prevention study data, 16, 412
- stent thrombosis study data, 40
- subacute thrombosis rates, 40
Asymmetric dimethylarginine (ADMA), 231-232
Atherectomy, 8, 214
Atherosclerosis
AAA vs stenotic, 119-121
adaptive immunity in, 109-110
adhesion molecules in, 200
animal models of, 143-144
as inflammatory disease, 86-89, 200
- bone marrow-derived SMC-like cells in, 189-190
- CD 40-CD 154
- pathway, 102-105
- chemokines and, 121, 200
- Chlamydia pneumoniae in, 114, 119
- CRP function in, 118
- cytokines in, 200
and diabetes, 235
- diagnostic imaging, 260-262
- diffuse intimai thickening in, 200
- endothelial cells in, 200
- eNOS and, 233-234
- EPCs and, 202-203
- HCMV in, 113, 119
- Helicobacter pylori in, 114
- hygiene hypothesis, 112-113
- hypercholesterolemia and, 118-119
- immune system involvement, animal models of, 109
- infectious pathogens in, 113, 115-116, 120
- innate immunity in, 109-110
- interleukin-10
- in, 112
- macrophages in, 200
- MHC class II expression in, 101
- mouse models, 115, 116, 189-190, 233-234
- MPI in, 260-262
- MyD 88
- pathway, 90, 91, 95, 104, 115, 116
- nonpathogenic microbes in, 109, 112
- oxLDL as, therapy, 117, 121, 233
- pathogen burden in, 114-115
- peptidoglycan in, 112, 116
- rabbit models, 233
- shear stress in, 62-63
- T-cells in, 96
- TLRsin, 115-116
AVAIL study, 402
AVI-4106, 401-402
BBaboon models
- endo vascular grafts, 69
- linear regression evaluation, 143
- thrombus formation, 137
Balloon angioplasty
- aerobic exercise and, 76
- antisense ODN delivery, 400
- collagen synthesis following, 215-216
- in diabetics, 55
- flow measurement technique, 279
- history of, 3
- PCI effectiveness studies, 264
- remodeling after, 19-20, 213-217, 336
- restenosis
- causes of, 48, 307
- identification of, 266-267
- prediction of, 266
- rates, 412
- shear stress collateral circulation role, 67
- flow eddies, 66-67
- vascular changes, 64-66
Balloon catheters
- channeled, 428, 429, 436
- double, 422-424, 435, 436
- hydrogel angioplasty, 429-431, 436, 437
- Infusa-Sleeve, 428-430
- porous/microporous, 425-428, 435-437
BARI trial, 9
Basic fibroblast growth factor (bFGF) in angiogenesis promotion, 237
- in intimai hyperplasia, 16-18
- response to shear stress, 65
- and SMC migration, 398
- in VSMC hyperplasia, 201
Batimastat DES
- clinical studies of, 356, 362
- neointimal accumulation study data, 18
- remodeling study data, 21, 216-217
ß-Blockers in MSCT imaging, 288, 292
ß-Cath™ System, 317, 318, 320-323, 328
B-cells
- as APCs, 101, 108. See also Adaptive immunity
- maturation, regulation of, 96
- sirolimus inhibition of, 341
Benestent studies, 33, 369
BERT trial, 319, 322, 323
BEST BTK trial, 280-281
BH 4 , 231, 232
Biodegradable stents, 346, 369-375, 435
Bioinformatics, 154
Biolimus DES, 339, 343, 344
Biopterin, 231
BIOTRONIK stent, 280
Blooming effect, 294, 295
Bone marrow cells, 187-192, 202-203
Brachytherapy
[weiter lesen]